• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Tetraphase Pharmaceuticals

edit

Capitalizing on breakthrough synthetic chemistry, Tetraphase Pharmaceuticals is leveraging a dynamic drug engine targeted at several significant disease categories.

Recent Milestones

edit

• 
  Tetraphase Pharmaceuticals — BARDA biothreat contract could bring $40M to Tetraphase (1/25/12)
  Posted 1/25/12 at 7:14pm via masshightech.com
• 
  Tetraphase Pharmaceuticals — NIAID biothreat contract could bring $36M to Tetraphase (10/19/11)
  Posted 10/19/11 at 11:10pm via masshightech.com
• 
  Tetraphase Pharmaceuticals — has named Patrick Horn, formerly of Dyax Corp., as the company’s first chief medical officer (1/24/11)
  Posted 1/25/11 at 4:22am via masshightech.com
• 
  Tetraphase Pharmaceuticals — appointed a new member to its board of directors (10/13/10)
  Posted 10/14/10 at 6:53am via masshightech.com
• 
  Tetraphase Pharmaceuticals received $45M in Series C funding. (6/1/10)
  Posted 6/1/10 at 5:35pm via fiercebiotech.com
• 
  Tetraphase Pharmaceuticals received $15M in Series A funding. (8/7/08)
  Posted 12/31/08 at 9:16pm via equityhelpdesk.com

Videos

Screenshots

edit

Traffic Analytics

Compete

Sources

1. Equity Help Desk (equityhelpdesk.com) [edit]
2. Tetraphase hauls in $45M C round to back antibiotic work (fiercebiotech.com) [edit]
Tetraphase appoints former Sirtris exec Bohlin to board (masshightech.com) [edit]
Horn named chief medical officer at Tetraphase (masshightech.com) [edit]
NIAID biothreat contract could bring $36M to Tetraphase (masshightech.com) [edit]
BARDA biothreat contract could bring $40M to Tetraphase (masshightech.com) [edit]